Stanford Cancer Institute Breakthroughs in Cancer: Immunotherapy for Melanoma: Past, Present, Future

The Stanford Cancer Institute Breakthroughs in Cancer seminar series provides a platform for eminent leaders in oncology to share their insights with the Stanford community. Seminars highlight innovations across basic, translational, clinical, and population cancer science. 

Join us Tuesday, July 14, 4-5 p.m., at Munzer Auditorium, Beckman Center, or Zoom for a presentation by Jedd Wolchok, MD, PhD, director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

Dr. Wolchok has been a principal investigator in numerous pivotal clinical trials. He helped establish immunotherapy as a standard approach to cancer treatment and was instrumental in the clinical development that led to the FDA approval of ipilimumab and the combination of nivolumab and ipilimumab for advanced melanoma. His research focuses on investigating novel immunotherapies, identifying innovative ways to modulate the immune response to cancer, and uncovering the biological mechanisms that drive treatment response and resistance. His presentation will examine how T cell therapies are advancing in the treatment of solid tumors through target discovery, metabolic modulation, and exhaustion resistance.

The event is open to Stanford faculty, trainees, students, and staff.

Registration is encouraged.